Compare NCEL & PLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCEL | PLSM |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Switzerland | Israel |
| Employees | 4 | 63 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 23.2M |
| IPO Year | N/A | N/A |
| Metric | NCEL | PLSM |
|---|---|---|
| Price | $3.35 | $3.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 70.5K | 2.3K |
| Earning Date | 05-12-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $3.00 |
| 52 Week High | $5.12 | $6.85 |
| Indicator | NCEL | PLSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 42.12 |
| Support Level | $2.21 | $3.00 |
| Resistance Level | $4.38 | $3.93 |
| Average True Range (ATR) | 0.61 | 0.16 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 33.08 | 12.24 |
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.